**Core Concept**
Selective Estrogen Receptor Modulators (SERMs) are a class of compounds that interact with the estrogen receptor (ER) to produce tissue-selective estrogen agonist/antagonist activities. In the context of osteoporosis treatment, SERMs are used to mimic the beneficial effects of estrogen on bone density while minimizing the risks associated with estrogen therapy, such as endometrial cancer and thromboembolic events.

**Why the Correct Answer is Right**
Raloxifene, a second-generation SERM, is specifically approved for the prevention and treatment of osteoporosis in postmenopausal women. It acts as an estrogen agonist on bone tissue, promoting bone formation and density, while acting as an estrogen antagonist on breast and uterine tissues, reducing the risk of breast cancer and endometrial hyperplasia. Raloxifene also has a beneficial effect on lipid profiles by increasing high-density lipoprotein (HDL) cholesterol and reducing low-density lipoprotein (LDL) cholesterol.

**Why Each Wrong Option is Incorrect**
**Option A:** Tamoxifen is primarily used in the treatment and prevention of breast cancer, acting as an estrogen antagonist on breast tissue. While it has some beneficial effects on bone density, it is not specifically indicated for osteoporosis treatment.
**Option B:** Toremifene is another SERM used in the treatment of breast cancer, but it is not commonly used for osteoporosis treatment due to its side effect profile and lack of efficacy data.
**Option C:** Clomifene is a first-generation SERM used primarily for the treatment of infertility in women with polycystic ovary syndrome (PCOS), and it is not indicated for osteoporosis treatment.

**Clinical Pearl / High-Yield Fact**
SERMs like Raloxifene can increase the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), similar to estrogen therapy. Patients with a history of DVT or PE should be carefully evaluated before starting SERM therapy.

**Correct Answer: D. Raloxifene**